Evidence map›Paper›PMID 40222802›Full record

ReviewAdvances in kidney disease and health2025

Postdischarge Care of Acute Kidney Injury Survivors: An Opportunity for Targeted Nurse and Pharmacist Interventions.

Melanie M Manis, Jessica L Wallace, Emily F Boyd, Kaleab Z Abebe, Linda Fried, Paul M Palevsky, Paul T Conway, Edward J Horwitz, Kathleen D Liu, Chirag R Parikh and 6 more

Abstract readReview
In one paragraph

Review in Advances in kidney disease and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Melanie M ManisDepartment of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL.
Jessica L WallaceDepartment of Pharmacy and Pharmaceutical Sciences, Lipscomb University College of Pharmacy, Nashville, TN; Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN; Division of Nephrology, Tennessee Valley Healthcare System (TVHS), Veterans Health Administration, Nashville, TN.
Emily F BoydDivision of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN.
Kaleab Z AbebeCenter for Clinical Trials and Data Coordination, Division of General Internal Medicine, University of Pittsburgh School of Medicine.
Linda FriedRenal-Electrolyte Division, University of Pittsburgh School of Medicine; Kidney Medicine Section, VA Pittsburgh Healthcare System.
Paul M PalevskyRenal-Electrolyte Division, University of Pittsburgh School of Medicine; Kidney Medicine Section, VA Pittsburgh Healthcare System.
Paul T ConwayPolicy and Global Affairs, American Association of Kidney Patients (AAKP), Tampa, FL.
Edward J HorwitzDepartment of Nephrology, Metrohealth Medical Center, Cleveland, OH.
Kathleen D LiuDepartments of Medicine and Anesthesia, University of California, San Francisco, CA.
Chirag R ParikhDepartment of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD.
Emilio PoggioDepartment of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
Edward D SiewDivision of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN; Division of Nephrology, Tennessee Valley Healthcare System (TVHS), Veterans Health Administration, Nashville, TN.
Javier A NeyraDepartment of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL.
Matthew R WeirDivision of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
F Perry WilsonClinical and Translational Research Accelerator, Department of Medicine, Yale School of Medicine, New Haven, CT.
Sandra L Kane-GillDepartment of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA; Department of Pharmacy, UPMC, Pittsburgh, PA; Department of Critical Care Medicine, Program of Critical Care Nephrology, Pittsburgh, PA.

Funding

Pharmacology CoreU54AT008909 · NCCIH · WASHINGTON STATE UNIVERSITY · PI PAINE, MARY F · 2015 to 2024
$22.4M
Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI PREISIG, PATRICIA A · 2008 to 2022
$16.8M
The Pittsburgh Scientific and Data Research Center for the COPE-AKI Consortium (Pitt-SDRC)-SupplementU01DK130010 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kaleab Z Abebe, LINDA Faith FRIED · 2021 to 2026
$6.1M
The Southeastern Acute Kidney Injury (SEAK) Alliance for the COPE-AKI ConsortiumU01DK129989 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Javier A. Neyra, Edward D Siew · 2021 to 2026
$4.7M
UAB-UCSD O'Brien Center for Acute Kidney Injury ResearchU54DK137307 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PAUL W. SANDERS · 2023 to 2026
$4.4M
Post-Discharge Nephrology Follow-up for Improved OutcomesU01DK129984 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Chirag R Parikh · 2021 to 2026
$4.2M
Cleveland COPE-AKI Clinical CenterU01DK129980 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Sevag Demirjian, ANNE Marie HUML · 2021 to 2026
$4.1M
(MEnD-AKI) Multicenter Implementation of an Electronic Decision Support System for Drug-associated AKIR01DK121730 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BIHORAC, AZRA, KANE-GILL, SANDRA L · 2021 to 2025
$3.2M
Optimizing Electronic Alerts for Acute Kidney InjuryR01DK113191 · NIDDK · YALE UNIVERSITY · PI WILSON, FRANCIS PERRY · 2018 to 2022
$3.1M
Artificial Intelligence to Predict Outcomes in Patients with Acute Kidney Injury on Continuous Renal Replacement TherapyR01DK133539 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Girish Nitin Nadkarni, Javier A. Neyra · 2023 to 2026
$2.6M
The Relation of Soluble Klotho with Cardiovascular Disease, Chronic Kidney Disease Progression, and Blood Pressure in the Systolic Blood Pressure Intervention TrialR01DK128208 · NIDDK · TUFTS MEDICAL CENTER · PI DREW, DAVID ALAN, NEYRA, JAVIER A. · 2021 to 2025
$1.6M
AHRQ HHS R01 HS027626NCCIH NIH HHS U54 AT008909NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK113191NIDDK NIH HHS R01 DK121730NIDDK NIH HHS R01 DK128208NIDDK NIH HHS R01 DK133539NIDDK NIH HHS U01 DK129980NIDDK NIH HHS U01 DK129984NIDDK NIH HHS U01 DK129989NIDDK NIH HHS U01 DK130010NIDDK NIH HHS U54 DK137307
6 · The paper itself

Abstract

The incidence of acute kidney injury (AKI) is increasing, and with it, the population of individuals requiring post-AKI care. Postdischarge follow-up for AKI survivors is recommended within 90 days of an AKI episode to promote kidney recovery and potentially prevent progression of kidney disease. However, timely postdischarge care is often lacking or fragmented and poses a missed opportunity to prevent long-term complications of this condition. Suggested elements of follow-up care begin with a scheduled appointment with a physician and involve a bundled approach to care with health care providers' communicating across sites, remote patient monitoring devices, review of medications, education, access, kidney care evaluation, and interdisciplinary collaboration to achieve these patient care goals. This article provides an overview of guidance documents for post-AKI care and the roles of the nurse and pharmacist as part of an interdisciplinary team in postdischarge care after a patient incurs an episode of AKI.

Indexed as

Acute Kidney InjuryAftercarePatient DischargePharmacistsHumansNurse's RolePatient Care TeamProfessional RoleSurvivorsAcute kidney injuryNursesPharmacistsTelemedicineTransitional care

Identifiers

PMID40222802
PMCPMC12120554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.